InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

- Current share price for ATX : $0.155

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$80 Amplia Announces $3.8m Share Placement 4 May 2021 9:49AM $0.285 $0.155 fallen by 45.61%
$80 Trading Halt 30 Apr 2021 9:22AM $0.285 $0.155 fallen by 45.61%
$80 Preclinical Data Support Developmnt AMP945 Pancreatic Cancer 28 Apr 2021 8:25AM $0.245 $0.155 fallen by 36.73%
$80 Quarterly Report and Shareholder Update 28 Apr 2021 8:24AM $0.245 $0.155 fallen by 36.73%
$80 Initial Director's Interest Notice - Jane Bell 22 Apr 2021 4:39PM $0.250 $0.155 fallen by 38%
$80 Shareholder Update and Presentation 22 Apr 2021 9:36AM $0.240 $0.155 fallen by 35.42%
$80 ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH 20 Apr 2021 8:25AM $0.230 $0.155 fallen by 32.61%
$80 Amplia Completes Dosing in Phase 1 Clinical Study of AMP945 15 Apr 2021 8:22AM $0.225 $0.155 fallen by 31.11%
$80 Amplia Appoints New Non-Executive Director 12 Apr 2021 8:48AM $0.255 $0.155 fallen by 39.22%
$80 Change of Registered Office and Principal Place of Business 25 Mar 2021 12:03PM $0.260 $0.155 fallen by 40.38%
$80 Appendix 2A - Exercise of Options 24 Mar 2021 2:42PM $0.260 $0.155 fallen by 40.38%
$80 Amplia and Garvan Institute Enter Collaboration Agreement 18 Mar 2021 8:24AM $0.260 $0.155 fallen by 40.38%
$80 Amplia Completes Single Dose Study of AMP945 17 Mar 2021 8:56AM $0.255 $0.155 fallen by 39.22%
$80 Amplia Initiates Multiple Dose Study of AMP945 17 Feb 2021 8:07AM $0.270 $0.155 fallen by 42.59%
$80 Appendix 2A - Exercise of Options 16 Feb 2021 4:20PM $0.270 $0.155 fallen by 42.59%
$80 Investor Update - February 2021 11 Feb 2021 9:41AM $0.270 $0.155 fallen by 42.59%
$80 Quarterly Activities and Cashflow Reports - Dec 2020 Qtr 28 Jan 2021 9:59AM $0.295 $0.155 fallen by 47.46%
$80 Appendix 2A - Exercise of Options 11 Jan 2021 1:21PM $0.260 $0.155 fallen by 40.38%
$80 Shareholder Update - 2020 Review 17 Dec 2020 8:21AM $0.230 $0.155 fallen by 32.61%
$80 Amplia Receives $0.53m R&D Tax Incentive 2 Dec 2020 9:20AM $0.225 $0.155 fallen by 31.11%
$80 Appendix 4D and Financial Report Half Year Ended 30 Sep 2020 27 Nov 2020 4:59PM $0.215 $0.155 fallen by 27.91%
$80 Appendix 2A - Allot Shares upon Exercise of Options 24 Nov 2020 6:51PM $0.220 $0.155 fallen by 29.55%
$80 Notice ASX LR 3.11.2 - Change of Exercise Price of Options 2 Nov 2020 5:05PM $0.200 $0.155 fallen by 22.50%
$80 ATX - Sep 2020 Quarter Activities and Cashflow Reports 29 Oct 2020 10:03AM $0.180 $0.155 fallen by 13.89%
$80 Amplia Presentation to Reach Market Services - Meet the CEO 21 Oct 2020 10:06AM $0.305 $0.155 fallen by 49.18%

376 - 400 of 537 results

Page 16 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.